/ny_teaser_oct_08.gif)
/Your_Chance_to_Get_in_the_MVA_Newsletter.gif)
/Subscribe_to_the_MVA_Newsletters.gif)
/Clinical_trial_470_x_80_(new).gif)
Clinical Trials Update provides you with latest news about clinical trials conducted by MVA members. The update gives insight to progress in studies, results and possible indications. As an MVA member please feel free to send us press releases for Clinical Trials Update at news@mva.org.
Read about the latest clinical trials below or use the archive in the bottom of the page to gain insight into past trials.
Medicon Valley Life Science
The Clinical Trials Update section is temporarely closed
2 July
Lundbeck: Lu AA24530 Shows Positive Results in Major Depressive Disorder Phase II Study
Read more (pdf)
25 June
Active Biotech and Teva Completes Enrollment in Second Oral Laquinimod Phase III MS Clinical Trial
25 June
Lundbeck Receives FDA Complete Response Letter on Serdolect for the Treatment of Schizophrenia
12 June
Genzyme Receives European Approval of Renvela for Patients with Chronic Kidney Disease
11 June
Active Biotech Presents Data Regarding the 57-57 SLE Project at EULAR
8 June
Update on Lundbeck's Lu AA21004 Clinical Development Programme in Major Depressive Disorder (MDD)
8 June
ALK's House Dust Mite Allergy Immunotherapy Tablet Shows Highly Beneficial Results in Asthma Patients (EAACI 2009)
8 June
Active Biotech Completes Patient Enrollment to TASQ Clinical Phase II Study
2 June
PROSTVAC Data Presented at the ASCO Meeting Demonstrates the Potential for Significant Increases in Life Expectancy in Late-Stage Prostate Cancer
2 June
Novo Nordisk to Conduct Study to Directly Compare Once-Daily Levemir With Another Basal Insulin Analogue
1 June
Active Biotech Completes Patient Enrollment to ANYARA Phase III Clinical Trial
20 May
Genzyme and Isis Announce that Mipomersen Phase 3 Study in Patients with Homozygous Familial Hypercholesterolemia Met Primary Endpoint
13 May
Data on Topotarget's Belinostat to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting
Read more (PDF)
11 May
AstraZeneca Announces Top Line Results from Pivotal Phase III Study for BRILINTA
8 May
Novo Nordisk's Levemir Once-Daily Substantially Lowered Average Blood Sugar Levels of Patients with Type 2 Diabetes in TITRATE Study
8 May
Studies of GARDASIL, Merck's Cervical Cancer Vaccine, and HPV 16 Vaccine Component of GARDASIL Presented at International Papillomavirus Conference
6 May
BioInvent Reports Positive Phase I Results for BI-204
Read more
6 May
ACADIA Pharmaceuticals and Biovail Announce Completion of Enrollment in First Pivotal Phase III Trial
Read more
29 April
NeuroSearch Demonstrates the Potential of ACR16 as a Novel Treatment for Huntington's Disease
28 April
AnaMar Medical Takes Significant Step with New Oral Cytokine Inhibitor to Treat Rheumatoid Arthritis
28 April
Active Biotech: New Data Illustrate Novel Mechanism of Action of Laquinimod, an Oral Compound for the Treatment of Multiple Sclerosis
28 April
Active Biotech Presents S100A9 as a Target for Quinoline Compounds
20 April
Santaris Pharma to Present Data on LNA-antimiRs at the American Association for Cancer Research 100th Annual Meeting 2009 in Colorado
16 April
Biogen Idec Recieves FDA Approval for TYSABRI High Titer Production
16 April
First Patient Dosed in TopoTargets Randomized BelCaP Study in CUP (Carcinoma of Unknown Primary site)
15 April
Biogen Idec Showcases Leading Multiple Sclerosis Franchise and Pipeline at the 61st Annual Meeting of the American Academy of Neurology
31 March
NeuroSearch : Recruitment Successfully Completed in Phase III Study with ACR16 in Huntington's Disease
23 March
Santaris Pharma's Fourth LNA-based RNA Inhibitor Enters Clinical Trials
18 March
Evolva starts Phase I Clinical Trials on EV-077
16 March
Positive update of TopoTarget's initial phase II study with belinostat in PTCL and CTCL supports the registration plan in PTCL
16 March
TopoTarget Reports Phase II Trial Results with Avugane in Acne Vulgaris
3 March
Bavarian Nordic has Agreed a Pathway for the Licensure of IMVAMUNE with the FDA After Successful Phase II Meeting
27 February
BioInvent Presents Positive Preclinical Data for BI-505 in Myelomav
24 February
Camarus Initiates a Phase I/II Clinical Trial of CAM2038
23 February
Bavarian Nordic Updates on Phase I/II Studies with Breast Cancer Vaccine
23 February
BioInvent and ThromboGenics Start Phase II Trial of TB-402
20 February
Genzyme's Oral Compound for Gaucher Disease Meets Primary Endpoint in Phase II Study
12 February
Oral Laquinimod for Multiple Sclerosis Granted Fast Track Status by FDA
11 February
NeuroSearch Announces Results from Phase II Studies of ABT-894 in Diabetic Neuropathic Pain
3 February
Zealand Pharma A/S Advances ZP1848 for the Prevention and Treatment of Inflammatory Bowel Disease into Phase I Clinical Trials
Archive
2008
Earlier issues are available through our news archive.
/Anne_Katrine_til_teaser.jpg)
|
Anne Katrine Nørgaard T: +45 3287 8003 M: +45 2875 4155 |
/LanguageWire_right_teaser_230.gif)